Antipodes Partners
MEDP icon

Antipodes Partners’s Medpace MEDP Stock Holding History

Antipodes Partners’s Portfolio MEDP Stock Details MEDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$16.9K Buy
+27
New +$15.8K ﹤0.01% 141

Other funds holding MEDP

Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return

Antipodes Partners's MEDP Position: Q3 2026 in Review

Antipodes Partners opened a new position in Medpace (MEDP) in Q3 2026: 27 shares worth $16.9K. The stake represents ﹤0.01% of the portfolio and ranks #141 among its holdings.

595 funds tracked by Wall St. Rank hold MEDP as of Q3 2026.

  • Antipodes Partners held 27 shares of Medpace worth $16.9K as of Q3 2026.
  • Medpace was a new Antipodes Partners position in Q3 2026.
  • Medpace made up ﹤0.01% of Antipodes Partners's portfolio in Q3 2026, its #141 holding.
  • 595 funds tracked by Wall St. Rank held Medpace as of Q3 2026.

Based on Antipodes Partners's 13F filing for Q3 2026, filed 5 Nov 2026.